Benita C Percival1, Yvonne L Latour2, Cynthia J Tifft3, Martin Grootveld1. 1. Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, UK. 2. Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN 37232-0252, USA. 3. Deputy Clinical Director, National Human Genome Research Institute, Director, National Institutes of Health, Bethesda, MD 20892-1205, USA.
Abstract
Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of GM1 gangliosidosis type 2 (GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for this disorder, we employed an untargeted, multi-analyte approach involving high-resolution 1H NMR analysis coupled to a range of multivariate analysis and computational intelligence technique (CIT) strategies to explore biomolecular distinctions between blood plasma samples collected from GM1T2 and healthy control (HC) participants (n = 10 and 28, respectively). The relationship of these differences to metabolic mechanisms underlying the pathogenesis of GM1T2 disorder was also investigated. 1H NMR-linked metabolomics analyses revealed significant GM1T2-mediated dysregulations in ≥13 blood plasma metabolites (corrected p < 0.04), and these included significant upregulations in 7 amino acids, and downregulations in lipoprotein-associated triacylglycerols and alanine. Indeed, results acquired demonstrated a profound distinctiveness between the GM1T2 and HC profiles. Additionally, employment of a genome-scale network model of human metabolism provided evidence that perturbations to propanoate, ethanol, amino-sugar, aspartate, seleno-amino acid, glutathione and alanine metabolism, fatty acid biosynthesis, and most especially branched-chain amino acid degradation (p = 10-12-10-5) were the most important topologically-highlighted dysregulated pathways contributing towards GM1T2 disease pathology. Quantitative metabolite set enrichment analysis revealed that pathological locations associated with these dysfunctions were in the order fibroblasts > Golgi apparatus > mitochondria > spleen ≈ skeletal muscle ≈ muscle in general. In conclusion, results acquired demonstrated marked metabolic imbalances and alterations to energy demand, which are consistent with GM1T2 disease pathogenesis mechanisms.
Biomarkers currently available for the diagnosis, prognosis, and therapeutic monitoring of n class="Disease">GM1 gangliosidosis type 2 (n class="Chemical">GM1T2) disease are mainly limited to those discovered in targeted proteomic-based studies. In order to identify and establish new, predominantly low-molecular-mass biomarkers for this disorder, we employed an untargeted, multi-analyte approach involving high-resolution 1HNMR analysis coupled to a range of multivariate analysis and computational intelligence technique (CIT) strategies to explore biomolecular distinctions between blood plasma samples collected from GM1T2 and healthy control (HC) participants (n = 10 and 28, respectively). The relationship of these differences to metabolic mechanisms underlying the pathogenesis of GM1T2 disorder was also investigated. 1HNMR-linked metabolomics analyses revealed significant GM1T2-mediated dysregulations in ≥13 blood plasma metabolites (corrected p < 0.04), and these included significant upregulations in 7 amino acids, and downregulations in lipoprotein-associated triacylglycerols and alanine. Indeed, results acquired demonstrated a profound distinctiveness between the GM1T2 and HC profiles. Additionally, employment of a genome-scale network model of human metabolism provided evidence that perturbations to propanoate, ethanol, amino-sugar, aspartate, seleno-amino acid, glutathione and alanine metabolism, fatty acid biosynthesis, and most especially branched-chain amino acid degradation (p = 10-12-10-5) were the most important topologically-highlighted dysregulated pathways contributing towards GM1T2 disease pathology. Quantitative metabolite set enrichment analysis revealed that pathological locations associated with these dysfunctions were in the order fibroblasts > Golgi apparatus > mitochondria > spleen ≈ skeletal muscle ≈ muscle in general. In conclusion, results acquired demonstrated marked metabolic imbalances and alterations to energy demand, which are consistent with GM1T2 disease pathogenesis mechanisms.
Entities:
Keywords:
GM1 gangliosidosis; NMR-based metabolomics; biomarkers; lysosomal storage disorders; metabolite set enrichment analysis; nuclear magnetic resonance (NMR) analysis; validation
Authors: Iola F Duarte; Brian J Goodfellow; António Barros; John G Jones; Cristina Barosa; Luisa Diogo; Paula Garcia; Ana M Gil Journal: NMR Biomed Date: 2007-06 Impact factor: 4.044
Authors: Udo F H Engelke; Maria L F Liebrand-van Sambeek; Jan G N de Jong; Jules G Leroy; Eva Morava; Jan A M Smeitink; Ron A Wevers Journal: Clin Chem Date: 2003-11-18 Impact factor: 8.327
Authors: Jose Condori; Walter Acosta; Jorge Ayala; Varun Katta; Ashley Flory; Reid Martin; Jonathan Radin; Carole L Cramer; David N Radin Journal: Mol Genet Metab Date: 2015-12-08 Impact factor: 4.797
Authors: Ecem Kaya; David A Smith; Claire Smith; Lauren Morris; Tatiana Bremova-Ertl; Mario Cortina-Borja; Paul Fineran; Karl J Morten; Joanna Poulton; Barry Boland; John Spencer; Michael Strupp; Frances M Platt Journal: Brain Commun Date: 2020-12-20